T cells for suicide gene therapy: activation, functionality and clinical relevance

Area of Science:

• Immunology
• Cell Therapy
• Gene Therapy

Background:

• Graft-versus-host disease (GVHD) is a complication of donor lymphocyte infusion (DLI).
• T cells engineered with suicide genes can mitigate GVHD but may have reduced immune function after activation.
• Optimizing T-cell activation is crucial for maintaining therapeutic efficacy and safety.

Purpose of the Study:

• To compare the efficacy of different T-cell activation protocols for donor lymphocyte infusion.
• To evaluate T-cell subtype expansion, functionality, and gene transduction efficiency.
• To identify optimal activation methods for enhancing T-cell-based therapies.

Main Methods:

• T cells were purified using CD3 and CD4/CD8 antibodies.
• Cells were transduced with a GMP-grade CD34/HSV-TK vector.
• Activation protocols compared soluble vs. bead-coupled CD3/CD28 antibodies with varying IL-2 concentrations.

Main Results:

• Soluble antibody activation yielded a 50-fold T-cell expansion, while bead-coupled antibodies resulted in 2-4 fold expansion.
• Soluble antibodies with high IL-2 preferentially stimulated CD8+ T cells and reduced cytokine secretion.
• Bead-coupled antibodies with low IL-2 maintained CD4/CD8 ratio and preserved cytokine secretion, with homogenous transduction.

Conclusions:

• T-cell activation method significantly impacts expansion, subtype distribution, and functionality.
• Bead-coupled antibody activation appears superior for preserving T-cell function and homogenous gene transduction.
• Optimized activation protocols are essential for effective T-cell therapy in preventing GVHD.